Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Théo de Witte et al.|New England Journal of Medicine|2017Cited by 2.2k
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AMLSabine Käyser, Konstanze Döhner, Jürgen Krauter et al.|Blood|2010Cited by 485
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study GroupVerena I. Gaidzik, Konstanze Döhner, Lars Bullinger et al.|Journal of Clinical Oncology|2011Cited by 450
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantationRichard F. Schlenk, Konstanze Döhner, Sabine Käyser et al.|Blood|2014Cited by 400
Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study GroupJan Krönke, Konstanze Döhner, Richard F. Schlenk et al.|Journal of Clinical Oncology|2011Cited by 393